|
業務類別
|
Biotechnology |
|
業務概覽
|
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291. |
| 公司地址
| 11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032 |
| 電話號碼
| +1 317 659-0200 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.mbxbio.com |
| 員工數量
| 63 |
| Mr. Peter Kent Hawryluk |
President, Chief Executive Officer and Director |
美元 625.00K |
22/04/2026 |
| Dr. Salomon Azoulay, M.D. |
Chief Medical Officer |
美元 488.50K |
22/04/2026 |
| Mr. John W. Smither |
Interim Chief Financial Officer |
-- |
27/02/2026 |
|
|
| Dr. Tiba Aynechi, PhD |
Independent Director |
22/04/2026 |
| Mr. Peter Kent Hawryluk |
President, Chief Executive Officer and Director |
22/04/2026 |
| Dr. Ora H. Pescovitz, M.D. |
Independent Director |
22/04/2026 |
| Ms. Laurie D. Stelzer, M.B.A. |
Independent Director |
22/01/2026 |
| Mr. Patrick J. Heron |
Lead Independent Director |
22/04/2026 |
| Mr. Stephen L. Hoerter |
Chairman of the board |
22/04/2026 |
| Mr. Edward T. Mathers |
Independent Director |
22/04/2026 |
| Dr. Steven Ryder, M.D. |
Independent Director |
22/04/2026 |
|
|
|
|
